FI3999038T3 - Sydämen sarkomeerin inhibiittorin oraalisia formulaatioita - Google Patents
Sydämen sarkomeerin inhibiittorin oraalisia formulaatioita Download PDFInfo
- Publication number
- FI3999038T3 FI3999038T3 FIEP20753563.4T FI20753563T FI3999038T3 FI 3999038 T3 FI3999038 T3 FI 3999038T3 FI 20753563 T FI20753563 T FI 20753563T FI 3999038 T3 FI3999038 T3 FI 3999038T3
- Authority
- FI
- Finland
- Prior art keywords
- weight
- sodium
- intragranular
- core
- iii
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962875358P | 2019-07-17 | 2019-07-17 | |
| PCT/US2020/042389 WO2021011808A1 (en) | 2019-07-17 | 2020-07-16 | Cardiac sarcomere inhibitor oral formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3999038T3 true FI3999038T3 (fi) | 2024-02-21 |
Family
ID=71995104
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP20753563.4T FI3999038T3 (fi) | 2019-07-17 | 2020-07-16 | Sydämen sarkomeerin inhibiittorin oraalisia formulaatioita |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20220265612A1 (https=) |
| EP (1) | EP3999038B1 (https=) |
| JP (1) | JP7623342B2 (https=) |
| KR (1) | KR20220082804A (https=) |
| CN (1) | CN114765954B (https=) |
| AU (1) | AU2020315642B2 (https=) |
| BR (1) | BR112022000495A2 (https=) |
| CA (1) | CA3144972A1 (https=) |
| CL (1) | CL2022000108A1 (https=) |
| DK (1) | DK3999038T3 (https=) |
| ES (1) | ES2974542T3 (https=) |
| FI (1) | FI3999038T3 (https=) |
| HR (1) | HRP20240200T1 (https=) |
| HU (1) | HUE065712T2 (https=) |
| IL (1) | IL289884B2 (https=) |
| LT (1) | LT3999038T (https=) |
| MX (1) | MX2022000708A (https=) |
| PH (1) | PH12022550083A1 (https=) |
| PL (1) | PL3999038T3 (https=) |
| PT (1) | PT3999038T (https=) |
| RS (1) | RS65302B1 (https=) |
| SI (1) | SI3999038T1 (https=) |
| SM (1) | SMT202400107T1 (https=) |
| TW (1) | TW202519217A (https=) |
| WO (1) | WO2021011808A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019144041A1 (en) | 2018-01-19 | 2019-07-25 | Cytokinetics, Inc. | Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors |
| JP7610985B2 (ja) | 2018-06-26 | 2025-01-09 | サイトキネティックス， インコーポレイテッド | 心臓サルコメア阻害剤 |
| JP7438148B2 (ja) | 2018-06-26 | 2024-02-26 | サイトキネティックス， インコーポレイテッド | 心臓サルコメア阻害剤 |
| MA53491A (fr) | 2018-08-31 | 2021-09-15 | Cytokinetics Inc | Inhibiteurs de sarcomes cardiaques |
| CN117083275A (zh) | 2021-03-04 | 2023-11-17 | 赛特凯恩蒂克公司 | 心脏肌节抑制剂 |
| PT4370116T (pt) | 2021-07-16 | 2025-03-14 | Cytokinetics Inc | Regimes de administração de aficamten para o tratamento da cardiomiopatia hipertrófica obstrutiva |
| WO2024020468A1 (en) | 2022-07-20 | 2024-01-25 | Cytokinetics, Incorporated | Methods for treating non-obstructive hypertrophic cardiomyopathy |
| EP4565230A1 (en) | 2022-08-04 | 2025-06-11 | Cytokinetics, Inc. | Methods for treating obstructive hypertrophic cardiomyopathy |
| WO2024179422A1 (zh) * | 2023-03-02 | 2024-09-06 | 苏州科睿思制药有限公司 | Aficamten的共晶及其制备方法和用途 |
| US20250295639A1 (en) | 2024-03-20 | 2025-09-25 | Cytokinetics, Incorporated | Methods for treating heart diseases |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007027855A2 (en) * | 2005-09-01 | 2007-03-08 | Array Biopharma Inc. | Raf inhibitor compounds and methods of use thereof |
| NZ598744A (en) * | 2009-09-18 | 2013-11-29 | Sanofi Sa | (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability |
| US20130273096A1 (en) * | 2011-10-05 | 2013-10-17 | Bruce A. Daniels | Therapeutic Sulfated Polysaccharides, Compositions Thereof, and Methods for Treating Patients |
| WO2013112804A1 (en) * | 2012-01-25 | 2013-08-01 | Vertex Pharmaceuticals Incorporated | Formulations of 3-(6-(1-(2.2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
| US9199945B2 (en) * | 2013-06-21 | 2015-12-01 | MyoKardia, Inc. | Cycloalkyl-substituted pyrimidinedione compounds |
| US20170087180A1 (en) * | 2014-06-03 | 2017-03-30 | Sulfagenix, Inc. | Methods and compositions for treating nitric oxide deficiency disorders and related conditions |
| US9902702B2 (en) * | 2014-07-15 | 2018-02-27 | Bristol-Myers Squibb Company | Spirocycloheptanes as inhibitors of rock |
| ES2969565T3 (es) * | 2015-09-30 | 2024-12-13 | Max Planck Ges Zur Foerderung Derwissenschaften E V | Derivados heteroarílicos como inhibidores de la sepiapterina reductasa |
| WO2019144041A1 (en) * | 2018-01-19 | 2019-07-25 | Cytokinetics, Inc. | Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors |
-
2020
- 2020-07-16 RS RS20240236A patent/RS65302B1/sr unknown
- 2020-07-16 LT LTEPPCT/US2020/042389T patent/LT3999038T/lt unknown
- 2020-07-16 HR HRP20240200TT patent/HRP20240200T1/hr unknown
- 2020-07-16 EP EP20753563.4A patent/EP3999038B1/en active Active
- 2020-07-16 DK DK20753563.4T patent/DK3999038T3/da active
- 2020-07-16 PT PT207535634T patent/PT3999038T/pt unknown
- 2020-07-16 WO PCT/US2020/042389 patent/WO2021011808A1/en not_active Ceased
- 2020-07-16 KR KR1020227003543A patent/KR20220082804A/ko active Pending
- 2020-07-16 FI FIEP20753563.4T patent/FI3999038T3/fi active
- 2020-07-16 CN CN202080062806.7A patent/CN114765954B/zh active Active
- 2020-07-16 ES ES20753563T patent/ES2974542T3/es active Active
- 2020-07-16 BR BR112022000495A patent/BR112022000495A2/pt unknown
- 2020-07-16 HU HUE20753563A patent/HUE065712T2/hu unknown
- 2020-07-16 PH PH1/2022/550083A patent/PH12022550083A1/en unknown
- 2020-07-16 TW TW113138679A patent/TW202519217A/zh unknown
- 2020-07-16 US US17/627,600 patent/US20220265612A1/en active Pending
- 2020-07-16 MX MX2022000708A patent/MX2022000708A/es unknown
- 2020-07-16 AU AU2020315642A patent/AU2020315642B2/en active Active
- 2020-07-16 SM SM20240107T patent/SMT202400107T1/it unknown
- 2020-07-16 SI SI202030397T patent/SI3999038T1/sl unknown
- 2020-07-16 CA CA3144972A patent/CA3144972A1/en active Pending
- 2020-07-16 JP JP2022502218A patent/JP7623342B2/ja active Active
- 2020-07-16 PL PL20753563.4T patent/PL3999038T3/pl unknown
- 2020-07-16 IL IL289884A patent/IL289884B2/en unknown
-
2022
- 2022-01-15 CL CL2022000108A patent/CL2022000108A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PH12022550083A1 (en) | 2023-04-12 |
| PL3999038T3 (pl) | 2024-05-13 |
| TW202116307A (zh) | 2021-05-01 |
| RS65302B1 (sr) | 2024-04-30 |
| IL289884B1 (en) | 2025-09-01 |
| IL289884A (en) | 2022-03-01 |
| MX2022000708A (es) | 2022-02-23 |
| BR112022000495A2 (pt) | 2022-03-03 |
| IL289884B2 (en) | 2026-01-01 |
| NZ784934A (en) | 2025-03-28 |
| US20220265612A1 (en) | 2022-08-25 |
| AU2020315642B2 (en) | 2026-04-02 |
| CL2022000108A1 (es) | 2022-10-21 |
| DK3999038T3 (da) | 2024-03-18 |
| KR20220082804A (ko) | 2022-06-17 |
| HRP20240200T1 (hr) | 2024-04-26 |
| EP3999038A1 (en) | 2022-05-25 |
| ES2974542T3 (es) | 2024-06-27 |
| TW202519217A (zh) | 2025-05-16 |
| PT3999038T (pt) | 2024-03-14 |
| AU2020315642A1 (en) | 2022-03-03 |
| CN114765954B (zh) | 2024-01-02 |
| JP7623342B2 (ja) | 2025-01-28 |
| JP2022542804A (ja) | 2022-10-07 |
| EP3999038B1 (en) | 2024-01-10 |
| LT3999038T (lt) | 2024-03-25 |
| SMT202400107T1 (it) | 2024-05-14 |
| WO2021011808A1 (en) | 2021-01-21 |
| HUE065712T2 (hu) | 2024-06-28 |
| CA3144972A1 (en) | 2021-01-21 |
| SI3999038T1 (sl) | 2024-05-31 |
| CN114765954A (zh) | 2022-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3999038T3 (fi) | Sydämen sarkomeerin inhibiittorin oraalisia formulaatioita | |
| JP2022542804A5 (https=) | ||
| US20230011269A1 (en) | Pharmaceutical composition comprising a potent inhibitor of urat1 | |
| US11819577B2 (en) | Fixed dose pharmaceutical composition of valsartan and sacubitril | |
| JP2019526591A5 (https=) | ||
| JP2011507973A (ja) | アムロジピンとバルサルタンとの医薬組成物 | |
| US10617699B2 (en) | Oral formulation for the treatment of cardiovascular diseases | |
| US11576917B2 (en) | Pharmaceutical compositions comprising Ibrutinib | |
| AU2016231883B2 (en) | Pharmaceutical compositions of dimethyl fumarate | |
| US20120093878A1 (en) | Pharmaceutical compositions containing a biguanide and a thiazolidinedione | |
| US20090264460A1 (en) | Clopidogrel pharmaceutical formulations | |
| CA2802831C (en) | Controlled release coat-core tablet | |
| WO2010120963A1 (en) | Tablet formulation for p38 inhibitor and method | |
| US20100297195A1 (en) | Controlled release lamotrigine formulations | |
| US20210267908A1 (en) | Pharmaceutical compositions of rivaroxaban | |
| KR20210079216A (ko) | 시벤졸린 또는 이의 염을 포함하는 약학 제형 | |
| RU2022103864A (ru) | Пероральные композиции ингибиторов сердечного саркомера | |
| AU2006307470A1 (en) | Pharmaceutical formulation of losartan | |
| RU2019144196A (ru) | Фармацевтическая композиция, содержащая ремоглифлозин и противодиабетическое средство | |
| WO2022153330A1 (en) | Pharmaceutical compositions comprising acalabrutinib | |
| NZ784934B2 (en) | Cardiac sarcomere inhibitor oral formulations | |
| WO2007049291A1 (en) | Novel solid dosage forms of valsartan and rochlorothiazide | |
| JP6824816B2 (ja) | 口腔内崩壊性被覆錠剤及び口腔内崩壊性被覆錠剤の被覆層用組成物 | |
| US20180098982A1 (en) | Oral pharmaceutical composition of methylergonovine and methods of use thereof | |
| WO2013054178A9 (en) | Extended release pharmaceutical compositions containing carbamazepine |